Jam

Ares Management Corporation is investing €2 billion for a 20% stake in Plenitude, a European energy transition leader controlled by Eni, valuing the company at €12 billion. Plenitude operates in 15 countries, with a significant renewable energy capacity and EV charging infrastructure. Ares’s Alternative Credit funds are leading the investment, supporting Plenitude’s growth strategy.

Minjee Lee secured her third major championship at the KPMG Women’s PGA Championship using Callaway equipment. Her winning performance featured an Elyte Driver, Chrome Tour X Golf Ball, and Odyssey Ai-ONE putter. Callaway was the leading driver brand, with the Chrome Tour X ball playing a crucial role. The victory adds to the Chrome Tour’s major wins, showcasing Callaway’s dominance in professional golf.

Loop Industries announced a $1.5 million engineering services agreement with ELITe, its Indian joint venture, to support the construction of its Infinite Loop™ India facility. The deal follows a completed initial agreement and highlights engineering services as a key revenue source. Loop is also pursuing off-take agreements with major brands for the India JV to solidify its position in sustainable materials. Ground-breaking is anticipated in the latter half of 2025.

Tigo Energy and BayWa r.e. will co-exhibit at ASEAN Sustainable Energy Week 2025 in Bangkok, Thailand. They will showcase solar solutions for C&I installers and EPCs, focusing on rapid shutdown regulations, high-wattage modules, and Total Quality Solar. Tigo’s TS4-X MLPE devices will be highlighted, offering optimization, monitoring, and safety features for Southeast Asia’s demanding climate. The Green Glove service program will also be promoted to support C&I system installers.

Molecular Partners, in collaboration with Orano Med, is advancing its Radio-DARPin candidate, MP0726, which targets mesothelin (MSLN) for ovarian cancer treatment. Preclinical data reveals promising tumor accumulation and favorable biodistribution, including a high tumor-to-kidney ratio. The program leverages Molecular Partners’ Radio-DARPin platform, designed to improve the delivery of radioactive payloads to solid tumors. MP0726’s preclinical data is to be presented at the 2025 SNMMI Annual Meeting.

Lilly announced positive Phase 3 trial results for once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes. The QWINT-1, QWINT-3, and QWINT-4 trials demonstrated non-inferior A1C reduction compared to daily basal insulin. The company plans to submit efsitora for regulatory review by the end of the year.

Innovent Biologics will present at the ADA’s 85th Scientific Sessions, unveiling research on its pipeline for metabolic disease. Key highlights include IBI3030, a novel anti-PCSK9 antibody conjugate, and promising results on mazdutide, a dual GCG/GLP-1 receptor agonist. Mazdutide data will focus on liver fat reduction, MASH and fibrosis improvement, and uric acid reduction. The presentation will feature results from preclinical studies and investigator-initiated trials, pointing to Innovent’s focus on innovative metabolic disease therapies.

U-Haul is providing 30 days of free self-storage and U-Box container usage in North Dakota and Minnesota to assist residents affected by recent tornadoes and a derecho. The company aims to help communities impacted by severe weather, offering secure storage for belongings during recovery. This complimentary offer applies to new rentals, with details on participating locations available in the provided list.

BioAge Labs presents preclinical data demonstrating apelin receptor (APJ) agonist potential for diabetic obesity and heart failure with preserved ejection fraction (HFpEF). APJ activation, acting as an exercise mimetic, enhances the effects of incretin therapy, improving glycemic control and offering cardioprotective benefits. The company is developing next-generation APJ agonists, including oral and injectable formulations, with an IND filing planned for 2026, aiming to develop new therapies for obesity and its complications.

Eli Lilly announced positive Phase 3 results for orforglipron, a once-daily oral drug for type 2 diabetes. The ACHIEVE-1 trial showed the drug lowered A1C levels (1.3-1.6% reduction) in four weeks and promoted weight loss (up to 7.9%). The safety profile was consistent with existing GLP-1 medications. Lilly plans further studies, positioning orforglipron as a potential competitor in the diabetes and weight-loss treatment market.